PTSD

Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia

Retrieved on: 
Thursday, December 21, 2023
Psilocybin, Atypical depression, Post-traumatic stress disorder, Treatment, FDA, Ethics, MDMA, PTSD, TGA, Clarion, Authorization, IHL, Patient, Therapeutic Goods Administration, TRD, Environment, Pharmaceutical industry

MELBOURNE, Australia and NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet needs is pleased to announce that it has received ethics board endorsement for psychedelic assisted therapy at its first clinic based in Melbourne, Australia, a city of approximately 5.2M people.

Key Points: 
  • Incannex subsidiary, Clarion Clinics, has received Human Research Ethics Committee (HREC) endorsement for administration of psychedelic-assisted therapies for TRD and PTSD.
  • Clarion Clinics is the only dedicated psychedelic-assisted therapy clinic in Australia, with intentions to open more clinics across the country and internationally as legislation permits.
  • Clarion Clinics team includes pre-eminent psychedelic researchers, psychologists and psychiatrists whose expertise can not easily be replicated in Australia.
  • The Melbourne Clarion Clinic will be the first dedicated Psychedelic-assisted therapy clinic in Australia.

Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction

Retrieved on: 
Thursday, December 21, 2023
Bar-Ilan University, Cocaine, Depression, FDA, Crime, PLUR, Pharmaceutics, Plural, PLX, Brain, Drug, Research, Rat, BIRAD, PTSD, Anxiety, U.N, Neurogenesis, Cell, Neuron, PAD, Pharmaceutical industry

Under the agreement, Bar-Ilan University via BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.

Key Points: 
  • Under the agreement, Bar-Ilan University via BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.
  • The agreement stems from a collaboration between Pluri and Bar-Ilan University researchers that presented compelling findings.
  • The studies evaluated PLX-PAD cells’ efficacy in treating cocaine addiction in animal models.
  • Across North America and Europe, demand for treatment has steadily increased over the last decade, according to the U.N. Office on Drugs and Crime.

Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

Retrieved on: 
Tuesday, December 19, 2023
Trauma, The Institute, Psilocybin, Lead, Psychiatrist, Mental health, PTSD, Sunstone, Post-traumatic stress disorder, Psychology, Safety, Patient, CMPS, Pharmaceutical industry

This is believed to be the first study reporting on the feasibility of psilocybin as a potential treatment for PTSD.

Key Points: 
  • This is believed to be the first study reporting on the feasibility of psilocybin as a potential treatment for PTSD.
  • The open-label study evaluated the safety and tolerability of COMP360 psilocybin treatment in patients with PTSD as a result of trauma experienced as adults.
  • 22 participants received a single 25mg dose of investigational COMP360 psilocybin treatment.
  • It’s encouraging to see these initial safety results for COMP360 psilocybin treatment in this patient population and we look forward to a more detailed analysis of the study next year.”

Beckley Academy Welcomes New Faculty for 2024 Psychedelic Therapy Practitioners Courses

Retrieved on: 
Thursday, December 14, 2023
Veteran, Faculty, Beckley Foundation, LCSW, Woman, MAPS, Research, Cognitive behavioral therapy, Ketamine, Psilocybin, LPC, Social justice, CIIS, MDMA, Refugee, PTSD, Human, Course, Patient, Safety, PAT, BIPOC, Education, Nursing

Both Sara and Mary are psychedelic therapists with clinical experience working with training organizations to meet the increasing demand for experienced and credentialed therapists able to train practitioners in the administration and facilitation of psychedelic therapies.

Key Points: 
  • Both Sara and Mary are psychedelic therapists with clinical experience working with training organizations to meet the increasing demand for experienced and credentialed therapists able to train practitioners in the administration and facilitation of psychedelic therapies.
  • Mary has completed training at CIIS CPTR, MAPS, and the Ketamine Training Center and is certified in Trauma-Focused Cognitive Behavioral Therapy.
  • Sara Gael Beauregard, MA, LPC, is a psychedelic therapist, educator, and mentor with expertise in MDMA-Assisted Therapy, ketamine-assisted therapy, and psychedelic risk reduction.
  • At Beckley Academy, we foster the relationship between learners and faculty by approaching the online classroom as a time for rich discussion, reflection, and embodied skills practice,” said Deborah Gardner , Head of Education for Beckley Academy.

MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD

Retrieved on: 
Wednesday, December 13, 2023
Food, MAPS, Research, FDA, Ketamine, Psilocybin, NDA, SAN, New Drug Application, PTSD, Safety, PBC, Pharmaceutical industry

The nonprofit Multidisciplinary Association for Psychedelic Studies ( MAPS ) created MAPS PBC in 2014 to advance the research and drug development program for investigational MDMA-assisted therapy for PTSD.

Key Points: 
  • The nonprofit Multidisciplinary Association for Psychedelic Studies ( MAPS ) created MAPS PBC in 2014 to advance the research and drug development program for investigational MDMA-assisted therapy for PTSD.
  • When I started MAPS in 1986, the FDA was still blocking all research with psychedelics.
  • MAPS had to try, though we might never succeed, to gather sufficient data about the safety and efficacy of MDMA-assisted therapy to seek approval for prescription use.
  • No psychedelic-assisted therapy has been approved by the FDA or other regulatory authorities; no therapy works for everyone; and all therapies, even in clinical settings, carry risks.

Record-Breaking $700,000 Verdict by Mezrano Law Firm Redefines Justice in Personal Injury Cases

Retrieved on: 
Thursday, November 30, 2023
Injury, Policy, Diagnosis, PTSD, Trauma, Motivation, Post-traumatic stress disorder, Travel, Mental health, Nursing

Birmingham, Alabama, Nov. 30, 2023 (GLOBE NEWSWIRE) -- The Mezrano Law Firm, one of the top personal injury law firms in Alabama, has secured a record-breaking $700,000 verdict in Franklin County, eclipsing the previous benchmark of a $550,000 medical malpractice case.

Key Points: 
  • Birmingham, Alabama, Nov. 30, 2023 (GLOBE NEWSWIRE) -- The Mezrano Law Firm, one of the top personal injury law firms in Alabama, has secured a record-breaking $700,000 verdict in Franklin County, eclipsing the previous benchmark of a $550,000 medical malpractice case.
  • Lead counsel Steven Mezrano, alongside fellow Edge lawyers Leah Johnson and Brent Crumpton, spearheaded the trial, setting a new standard for personal injury cases in Franklin County.
  • This accomplishment underscores the Mezrano Law Firm's unwavering commitment to justice and fair compensation for its clients, solidifying its reputation as a legal powerhouse.
  • Established over 15 years ago, the Mezrano Law Firm has consistently demonstrated its dedication to its clients.

Mydecine Announces Update Regarding the Special Access Program

Retrieved on: 
Tuesday, November 28, 2023
NEO, API, Physician, Partnership, Hospital, News, MDMA, Mental health, PTSD, Engineering, Health Canada, Social media, Patient, OTC, Ground substance, Pharmaceutical industry

DENVER, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, wishes to clarify certain statements made in the Company’s news release of January 13, 2022 (the “Prior Release”) wherein the Company announced it would be launching the Special Access Support and Supply Program (“SASSP”) to provide products and services to physicians, clinics, and hospitals in Canada who are looking to treat patients through psychedelic-assisted psychotherapy.

Key Points: 
  • DENVER, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, wishes to clarify certain statements made in the Company’s news release of January 13, 2022 (the “Prior Release”) wherein the Company announced it would be launching the Special Access Support and Supply Program (“SASSP”) to provide products and services to physicians, clinics, and hospitals in Canada who are looking to treat patients through psychedelic-assisted psychotherapy.
  • The Company would like to clarify that the access to Health Canada’s Special Access Program (the “Program”) to assist potential patients with the use of Psilocybin and/or MDMA is exclusively through its partner, Applied Pharmaceutical Innovation (“API”) pursuant to the Health Canada license granted to Dr. Raimar Loebenberg (the “Partnership”).
  • Pursuant to the Partnership, API may provide patients access to certain controlled substances, including Psilocybin and/or MDMA, however, Mydecine does not directly have the ability to grant patients access to controlled substances through the Program.
  • The Company wishes to further clarify that any previous references to the Program in its press release, social media or website was not intended to promote the availability of unauthorized drugs to Canadians, nor to suggest that these unauthorized drugs have any authorized therapeutic uses in Canada.

America’s VetDogs Provides the Pentagon with Specially Trained Facility Dog

Retrieved on: 
Tuesday, November 28, 2023
Brooke Army Medical Center, Veteran, J-3, Joint Chiefs of Staff, Disability studies, Occupational therapy, Hearing, Disability, Dog, PTSD, Pentagon, Post-traumatic stress disorder, Madigan Army Medical Center, Chief of staff

Smithtown, NY and Washington, DC, Nov. 28, 2023 (GLOBE NEWSWIRE) -- America’s VetDogs is honored to place a specially trained facility dog at the Pentagon with J-3 Operations of the Joint Chiefs of Staff.

Key Points: 
  • Smithtown, NY and Washington, DC, Nov. 28, 2023 (GLOBE NEWSWIRE) -- America’s VetDogs is honored to place a specially trained facility dog at the Pentagon with J-3 Operations of the Joint Chiefs of Staff.
  • Charlie, a 2-year-old yellow Labrador Retriever, was specifically trained as a facility dog to provide animal assisted support for Pentagon personnel and visitors.
  • Charlie becomes the newest valued member of the America's VetDogs facility dog team, joining the ranks of more than 25 facility dogs, including honorary Chief Petty Officer Sully H.W.
  • “We are humbled to have an America’s VetDogs facility dog at the Pentagon to provide support to military and civilian personnel who serve our nation,” said John Miller, president and CEO, America’s VetDogs.

Healed Warrior Uses His Story to Inspire Others

Retrieved on: 
Wednesday, November 22, 2023
Well, Brooke Army Medical Center, Coma, Fisher House, Walking, Injury, Family, Intrepid, Divorce, Burn, Army, Defense, Hatboro, Pennsylvania, Amputation, PTSD, Privacy, Spine, Sleep, Face, Pelvis, IED

And then they finally were able to release me from the hospital and allow me to start at the Center for the Intrepid.

Key Points: 
  • And then they finally were able to release me from the hospital and allow me to start at the Center for the Intrepid.
  • That's for sure.”
    J.P. and his wife, Crystal, now spend their time traveling and telling his story to inspire others.
  • I am literally a walking example of being able to do so much.”
    “I'm not a wounded warrior.
  • I'm just a warrior, because I'm healed, and I'm even stronger than I used to be.

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

Retrieved on: 
Tuesday, November 21, 2023
Research, Patient safety, Nose, SILO, Brain, Anxiety, PTSD, Post-traumatic stress disorder, Nasal cavity, Silicon, Therapy, Area studies, Argyreia nervosa, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a new exclusive license agreement with medical technology manufacturer Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for Silo’s intranasal therapeutic drug SPC-15.

Key Points: 
  • “We began a collaboration with Medspray earlier this year for feasibility studies evaluating its patented technology as a delivery mechanism for our intranasal therapeutic drug SPC-15.
  • Based on successful outcomes from these studies, we have selected Medspray’s Spray Technology for our formulation,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • “As part of our manufacturing and sales contract, we have obtained exclusive rights to its spray mist technology for use with multiple indications including post-traumatic stress disorder (PTSD) and anxiety, as well as Alzheimer’s disease and anorexia.
  • The drug dispersion through the nose to brain has been designed to optimize patient safety and therapeutic delivery.